Click here to receive MS news via e-mail
May 6, 2017
Alemtuzumab improves long-term clinical and radiological outcomes in black patients with relapsing-remitting multiple sclerosis, according to data presented at the 69th Annual Meeting of the American Academy of Neurology in Boston, MA.
Black patients typically have more severe MS than white patients, characterized by more rapid disability accumulation, greater MRI lesion volumes, increased risk for secondary progression, accelerated retinal nerve fiber layer and ganglion cell/inner plexiform layer thinning, and the potential for a poorer response to disease-modifying therapies (DMTs).
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis. Join us by registering here: www.register.msviewsandnews.org